← All trials
NCT01328860
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2011
- Primary completion
- Jun 1, 2014
- Completion date
- Jun 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Memorial Hermann Health SystemLead sponsor
- Advent HealthCollaborator
- University of Texas at HoustonOverall official - principal investigator
- Memorial Hermann Health SystemSponsor investigator
- University of Texas at HoustonCollaborator
- The Institute for Rehabilitation and Research (TIRR) FoundationCollaborator
- Baylor UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.